Genomics Market Size, Share & Trends Analysis Report By Application & Technology (Functional Genomics, Pathway Analysis), By Deliverable (Products, Services), By End-use- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Genomics market size was estimated at USD 27.90 billion in 2021 and is expected to surpass around USD 96.25 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 20.9% during the forecast period 2022 to 2030.

Key Takeaways:

  • By Deliverable, the U.K. Genomics market was valued at USD 450.2 Million in 2021 and expected to witness growth at a CAGR of 17.2% from 2022 to 2030.
  • In the products segment, the consumables and reagents segment is expected to register the fastest CAGR over the forecast period owing to the high volume requirement for reagents and consumables for genomic analysis
  • In the services segment, NGS-based services dominated the market in 2021. The use of NGS-based services for the analysis of the SARS-CoV-2 genome drives the segment. The COVID-19 Genomics UK (COG-UK) Consortium delivers rapid and large-scale whole-genome sequencing of SARS-CoV-2
  • By application and technology, functional genomics led the market in 2021 due to the development of high-throughput technologies for the gene as well as protein studies. The generation of a large amount of sequencing data has led to significant developments in the segment
  • Based on end use, pharmaceutical and biotechnology companies dominated the market in 2021. Pharmaceutical and biotechnology companies like Menlo Park; Grail, Inc.; and Regeneron Pharmaceutical, Inc. have initiated large-scale genomic sequencing projects in collaboration with both community health systems and academic medical centers
  • Asia Pacific is expected to register the fastest growth rate from 2022 to 2030 owing to an increase in adoption and awareness about a number of genomics technologies in emerging countries, such as China and India, for the detection, treatment, and prognosis of various genetic disorders, such as diabetes and cancer

The scientific community has tried to address genetic susceptibility and severity to SARS-CoV-2 infection by combining research efforts using existing genetic databases. Multiomic-based approaches and genome-wide association studies (GWAS) have been employed to uncover biological networks and common variants underlying host-pathogen interactions. Similarly, data derived from genomes, such as polygenic risk scores (PRS), ABO blood groups, and HLA haplotypes, can be potentially used to decipher COVID-19 complications, resistance, and susceptibility. Moreover, biobanks that link electronic health records (EHRs) to genomic data can be leveraged to study the impact of genomic factors on the clinical course of patients infected with SARS-CoV-2.

The COVID-19 Host Genetics Initiative launched by researchers from the Finnish Institute for Molecular Medicine (FIMM) aims to inspire the human genetics community to analyze, share, and generate data to interpret determinants of COVID-19 outcomes, severity, and susceptibility. deCODE genetics, a genomics solutions provider in Iceland, has used SARS-CoV-2 genomic analysis to monitor the viral spread.

In addition, the company has partnered with the Government of Iceland to conduct genome sequencing of viral hosts. Similarly, the government of Greece funded the COVID-19-GR initiative to genotype 3,500 COVID-19 patients, conduct WGS on the SARS-CoV-2 genome obtained from these patients, and conduct immunogenomic analyses. The complete set of this data along with detailed clinical information is available and can be retrieved from the Greek COVID-19 registry.

In the near future, prenatal genetic screening programs are likely to grow at a significant pace. This is because these programs help expectant mothers identify chromosomal anomalies in their offspring. Moreover, it is anticipated that in the next 10 years, every newborn’s genome would be sequenced and stored in the electronic medical record. Gauging the future market potential of genomics in newborn screening programs, emerging companies like Counsyl and Natera have launched various genetic tests to maintain their competitive edge in the market.

Report Scope of the Genomics Market

Report Coverage


Market Size

US$ 96.25 Billion by 2030

Growth Rate

CAGR of 20.9% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year


Forecast Period

2022 to 2030

Segments Covered

 Application & technology, deliverable, end-use and Region,

Companies Mentioned

 Thermo Fisher Scientific, Inc.; Agilent Technologies; Beijing Genomics Institute (BGI); Bio-Rad Laboratories; Danaher Corporation; F. Hoffmann-La Roche Ltd.; GE Healthcare; Illumina, Inc.; Oxford Nanopore Technologies; Pacific Biosciences of California, Inc.; QIAGEN N.V.; Quest diagnostics; Myriad Genetics, Inc.; Eppendorf AG; Eurofins Scientific; Color; 23andMe, Inc.


Application & Technology Insights

Functional genomics held the largest revenue share of 33.0% in 2021. Real-time PCR was the dominant revenue generator within functional genomics. Real-time quantitative PCR has played a major role in the absolute quantification of genetic elements in genomic DNA. This technology has been employed to evaluate the use of tissue genomic DNA as a universal external standard for accelerating quantification of any target sequence in the genome of various species.

The use of this technology in combination with reverse transcription PCR enables quantification of low-abundance mRNA, which, in turn, allows researchers to quantify relative gene expression at a particular time. Since this technology is observed to be more sensitive than array technology, when it comes to the detection of small changes in gene expression, its adoption rate is continuously growing. However, it requires more input and is found to be less adaptable in high-throughput studies.

Pathway analysis is expected to register the fastest CAGR from 2021 to 2028. Investigation of how individual targets communicate and respond within the molecular networks has helped elaborate the functioning of biological processes at a cellular level. Hence, pathway analysis has become an integral aspect of drug development and life sciences research. The research community uses pathway analysis to improve fundamental understanding of cellular and molecular biology.

Deliverable Insights

The products segment dominated the market in 2021 with a revenue share of 70.3%. Continuous launch of nucleic acid extraction reagents and kits by key manufacturers is driving the revenue generation in the segment. For instance, in June 2020, Omega Bio-tek, Inc. introduced the Mag-Bind Viral RNA Xpress Kit for reliable and rapid viral RNA isolation from nasopharyngeal swab samples.

This introduction of a new kit helps overcome the scarcity of RNA purification kits that are used in the testing of COVID-19. Similarly, in April 2020, PHASE Scientific announced the global release of the PHASIFY VIRAL RNA Extraction Kit that is used to help in the detection and control of coronavirus. This kit allows purification and concentration of the viral nucleic acid in Viral Transport Media (VTM) samples of patients.

Similarly, in October 2020, QIAGEN NV announced the future launch of a novel kit to simplify and accelerate PCR-based analysis of COVID-19 and other RNA-based viruses. Such advancements in product offerings are anticipated to augment organic revenue generation in the market.

On the other hand, key players are acquiring smaller companies to advance their products in accordance with the latest technologies. For instance, in June 2020, Illumina, Inc. acquired Bluebee to boost genomic analysis. The cloud capability of Bluebee is expected to help in reducing the costs of sharing, storing, and managing genomic data in new products.

End-use Insights

Pharmaceutical and biotechnology companies held the largest share of 61.3% in 2021. Genomic technologies are witnessing high demand from pharmaceutical and biotechnology companies owing to the increasing number of genetic research studies. As genomics plays a crucial role in drug discovery and development, several drug developers are employing genomic techniques to ease and improve the process.

For the past few years, direct-to-consumer genomic tests are being offered by companies, resulting in the changing of business models. Personal genomics companies are generating genomics data to offer to pharmaceutical companies. With convenient data analysis and the availability of cheaper data acquisition, several new players have entered the genomics services market to meet the growing demand.

Furthermore, the market is witnessing increased demand for advanced gene-editing tools from biotechnology companies. Biotechnology companies are entering into strategic alliances or licensing partnerships to avail of this technology. For instance, in October 2020, Merck licensed CRISPR technology to Takara Bio USA, Inc. and PanCELLa, Canada. These licenses are aimed to boost the development of new therapies by improving drug discovery.

Similarly, in January 2020, New England Biolabs signed an agreement with ERS Genomics Limited for the commercialization of CRISPR gene editing reagents and tools. Thus, the market is witnessing increased adoption of genomic technologies by pharmaceutical and biotechnology companies.

Regional Insights

North America dominated the market with a share of 37.8% in 2021 owing to an increase in the number of research programs, a high number of strategic partnerships, and a rise in regulatory approvals by the U.S. FDA. Changing regulations for reimbursement and usage are anticipated to further propel the adoption of genetic tests in this region.

In January 2020, Color Genomics, Inc., in collaboration with NorthShore University HealthSystem, completed the delivery of clinical genomics in routine care under its U.S. program. The company has also supported Sanford's genomics program, Imagenetics, to improve clinical decision-making.

Asia Pacific is witnessing an increasing adoption of genomic technologies owing to the initiation of various research programs. The GenomeAsia 100K Project is one such project that includes whole-genome sequencing (WGS) to enable genetic discoveries across Asia. The study covered four different countries from Asia.

Moreover, supportive regulatory bodies are contributing to the market growth by increasing the number of approvals. In February 2020, the National Cancer Center (NCC) Japan collaborated with Foundation Medicine, along with Chugai Pharmaceutical, Ltd., to use FoundationOneLiquid in the third stage of Japan’s cancer genomic screening consortium. This enhanced the growth of the genomic testing services market in Japan.

Some of the prominent players in the Genomics Market include:

  • Thermo Fisher Scientific, Inc.
  • Agilent Technologies
  • Beijing Genomics Institute (BGI)
  • Bio-Rad Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Illumina, Inc.
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California, Inc.
  • Quest diagnostics
  • Myriad Genetics, Inc.
  • Eppendorf AG
  • Eurofins Scientific
  • Color
  • 23andMe, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Genomics market

  • Application & Technology
    • Functional Genomics
      • Real-time PCR
      • Transfection
      • SNP Analysis
      • Mutational Analysis
      • Microarray Analysis
      • RNA Interference
    • Pathway Analysis
      • Microarray Analysis
      • Bead-based Analysis
      • Proteomics Tools (2-D PAGE; yeast 2-hybrid studies)
      • Real-time PCR
    • Biomarker Discovery
      • DNA Sequencing
      • Microarray Analysis
      • Real-time PCR
      • Mass Spectrometry
      • Statistical Analysis
      • Bioinformatics
    • Epigenetics
      • Bisulfite Sequencing
      • Microarray Analysis
      • Chromatin Immunoprecipitation (ChIP & ChIP-Seq)
      • Methylated DNA Immunoprecipitation (MeDIP)
      • High Resolution Melt (HRM)
      • Chromatin Accessibility Assays
    • Others
  • Deliverable
    • Products
      • Instruments/Systems/Software
      • Consumables & Reagents
    • Services
      • NGS-based Services
      • Core Genomics Services
      • Biomarker Translation Services
      • Computational Services
      • Others
  • End-use
    • Pharmaceutical and Biotechnology Companies
    • Hospitals and Clinics
    • Academic and Government Institutes
    • Clinical Research
    • Other End Users

By Geography

North America

  • U.S.
  • Canada


  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Points Covered in Genomics Market Study:

  • Growth of Genomics in 2022
  • Market Estimates and Forecasts (2017-2030)
  •  Brand Share and Market Share Analysis
  •  Key Drivers and Restraints Shaping Market Growth
  •  Segment-wise, Country-wise, and Region-wise Analysis
  •  Competition Mapping and Benchmarking
  •  Recommendation on Key Winning Strategies
  •  COVID-19 Impact on Demand for Genomics and How to Navigate
  •  Key Product Innovations and Regulatory Climate
  •  Genomics Consumption Analysis
  •  Genomics Production Analysis
  •  Genomics and Management

Report Detail

  • Report Code:6825
  • No. of Pages:150+
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 3500
USD 7000